Doubles the positive rate for clinically actionable mutations compared to single syndrome testing1, without increasing healthcare costs2
Tools and statistical methods used in variant classification and reclassification demonstrate >99% confidence3-5
Vast majority of pathogenic variants (>99.8%) identified in genes with explicit professional society management recommendations1,6
Fact Sheets and Product Info:
Find more Myriad info as well as links to National Institutes of Health hereditary cancer resources.
About Hereditary Cancer:
Multiple genes can be associated with a single cancer. Multiple cancer risks can be associated with a single gene.
It is now recognized through an increasing amount of published literature that the same type of cancer or family history of cancer can be caused by mutations in different genes. As well, the characteristics of one hereditary cancer syndrome can overlap with those of another syndrome. With the technological advances in molecular diagnostics, testing for these additional genes can be performed simultaneously with BRCA1 and BRCA2.
MyRisk is proven to increase the identification of mutation carriers within the same National Comprehensive Cancer Network® recommended testing population.
One key feature is the test result that providers and patients receive. Instead of a test result indicating only whether the patient is positive or negative for a gene mutation, the MyRisk test provides a clinical decision support tool. This tool outlines patients’ cancer risks and the medical management recommendations endorsed by societal guidelines.
1. Rosenthal, E, et al. Cancer Genet. 2017 Dec;218-219:58-68.
2. Byfield, SD, et al. J Comp Eff Res. 2021 Feb;10(3):207-217.
3. Pruss D, et al. Breast Cancer Res Treat. 2014 Aug;147(1):119-32.
4. Morris B, et al. BMC Genet. 2016 Jul 1;17(1):99.
5. Esterling L, et al. JCO Precis Oncol. 2020 Aug;4:944-54.
6. Myriad Genetics data on file. Total clinical tests reported through 2020.